SynthesisFrontiers in medicine2025
Metabolomics biomarkers and related pathways in acute renal injury: a bibliometric investigation, meta-analysis, and systematic review.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics analysis identifies microbial dysbiosis and functional metabolic reprogramming in acute kidney injury.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Early diagnosis of Acute Kidney Injury (AKI) is critical for improving patient outcomes. This study aims to provide a comprehensive overview of the research landscape and to identify key metabolic biomarkers and pathways associated with AKI through bibliometric analysis and meta-analysis. Methods: We conducted a bibliometric analysis of scientific articles on metabolomics in AKI published between 2005 and 2025. Building on this bibliometric foundation, we performed a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to delve deeper into the synthesis of findings on diagnostic metabolites. Results: (1) Bibliometric analysis shows rapid growth and international collaboration in AKI metabolomics research. Studies focused on risk factors, management, and underlying mechanisms. (2) Meta-analysis reveals that decreased glycine, lysine, and cystine, along with increased tryptophan, distinguish AKI patients from healthy controls. These metabolites are sensitive diagnostic biomarkers. (3) Enriched pathways identified by Human Metabolome Database (HMDB) and Kyoto Encyclopedia of Genes and Genomes (KEGG) suggest that amino acid metabolism are key contributors to AKI pathogenesis. Discussion: This systematic review highlights the significant diagnostic and mechanistic value of metabolomics in AKI. The identified metabolite panel and associated pathways offer promising targets for early diagnosis and elucidate critical aspects of the disease's underlying biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.